SCLC患者-话题@MedSci

#SCLC患者#

174篇内容 | 2870人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2069042, encodeId=a18d2069042c0, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, objectType=article, longId=220896, objectId=74f1220896c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74f1220896c6, replyNumber=0, likeNumber=88, createdTime=2021-12-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74f1220896c6, moduleTitle=Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74f1220896c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069023, encodeId=a25d206902318, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), objectType=article, longId=215428, objectId=756f215428da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=756f215428da, replyNumber=0, likeNumber=67, createdTime=2021-10-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=756f215428da, moduleTitle=Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=756f215428da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069026, encodeId=60102069026ff, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Thorac Onco：奥希替尼单药抗NSCLC患者未放疗过的CNS转移灶的疗效, objectType=article, longId=216361, objectId=29db21636143, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29db21636143, replyNumber=0, likeNumber=65, createdTime=2021-09-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29db21636143, moduleTitle=J Thorac Onco：奥希替尼单药抗NSCLC患者未放疗过的CNS转移灶的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29db21636143)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069052, encodeId=14f2206905252, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=115, createdTime=2022-05-16, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069018, encodeId=ffad20690187e, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, objectType=article, longId=212499, objectId=bef02124990d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bef02124990d, replyNumber=0, likeNumber=62, createdTime=2022-04-17, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bef02124990d, moduleTitle=ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bef02124990d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069040, encodeId=257320690402c, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Clin Cancer Res：Tepotinib治疗MET外显子14 (METex14)跳跃NSCLC患者的疗效和安全性：VISION研究, objectType=article, longId=220835, objectId=9070220835a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9070220835a6, replyNumber=0, likeNumber=68, createdTime=2022-06-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9070220835a6, moduleTitle=Clin Cancer Res：Tepotinib治疗MET外显子14 (METex14)跳跃NSCLC患者的疗效和安全性：VISION研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9070220835a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069020, encodeId=df062069020e6, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究, objectType=article, longId=213586, objectId=462521358613, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=462521358613, replyNumber=0, likeNumber=60, createdTime=2021-10-26, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=462521358613, moduleTitle=Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=462521358613)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069010, encodeId=aab1206901029, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, objectType=article, longId=210605, objectId=efad2106052b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efad2106052b, replyNumber=0, likeNumber=72, createdTime=2022-03-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efad2106052b, moduleTitle=J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efad2106052b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069011, encodeId=208520690114a, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效, objectType=article, longId=210739, objectId=ba42210e39c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba42210e39c8, replyNumber=0, likeNumber=79, createdTime=2021-10-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba42210e39c8, moduleTitle=J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba42210e39c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069025, encodeId=ba292069025c8, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）, objectType=article, longId=215743, objectId=7f20215e43ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f20215e43ec, replyNumber=0, likeNumber=103, createdTime=2022-05-19, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f20215e43ec, moduleTitle=Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f20215e43ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069019, encodeId=cd10206901940, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, objectType=article, longId=213343, objectId=818f213343eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=818f213343eb, replyNumber=0, likeNumber=68, createdTime=2021-09-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=818f213343eb, moduleTitle=JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=818f213343eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069035, encodeId=9ff6206903544, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, objectType=article, longId=218184, objectId=5824218184a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5824218184a3, replyNumber=0, likeNumber=75, createdTime=2022-08-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5824218184a3, moduleTitle=Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5824218184a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069013, encodeId=eef5206901375, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, objectType=article, longId=211341, objectId=0e6621134127, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e6621134127, replyNumber=0, likeNumber=44, createdTime=2021-11-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e6621134127, moduleTitle=J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e6621134127)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069007, encodeId=66e0206900e00, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Immunother Cancer：抗生素对派姆单抗治疗的NSCLC患者的预后具有显著的负性效应！, objectType=article, longId=209752, objectId=c7c0209e52a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7c0209e52a2, replyNumber=0, likeNumber=63, createdTime=2022-03-22, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7c0209e52a2, moduleTitle=J Immunother Cancer：抗生素对派姆单抗治疗的NSCLC患者的预后具有显著的负性效应！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7c0209e52a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069008, encodeId=56482069008e7, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=AACR年会：新辅助免疫治疗将NSCLC患者的病理完全反应率提高12倍！, objectType=article, longId=209948, objectId=f16820994893, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f16820994893, replyNumber=0, likeNumber=73, createdTime=2022-02-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f16820994893, moduleTitle=AACR年会：新辅助免疫治疗将NSCLC患者的病理完全反应率提高12倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f16820994893)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069022, encodeId=1af1206902209, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=J Clin Oncol：晚期NSCLC患者围手术期加用度伐单抗显著提高了1年EFS率, objectType=article, longId=214458, objectId=eb97214458d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb97214458d9, replyNumber=0, likeNumber=71, createdTime=2022-06-18, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb97214458d9, moduleTitle=J Clin Oncol：晚期NSCLC患者围手术期加用度伐单抗显著提高了1年EFS率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb97214458d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069001, encodeId=c7462069001f4, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, objectType=article, longId=206667, objectId=b05220666ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b05220666ed0, replyNumber=0, likeNumber=88, createdTime=2021-05-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b05220666ed0, moduleTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b05220666ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069017, encodeId=7826206901e8b, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存, objectType=article, longId=212488, objectId=df61212488ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df61212488ed, replyNumber=0, likeNumber=62, createdTime=2022-04-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df61212488ed, moduleTitle=ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df61212488ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069014, encodeId=8c4d20690149f, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Lancet Oncol：杜鲁伐单抗联合立体定向放疗明显改善早期NSCLC患者预后, objectType=article, longId=211558, objectId=a63921155892, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a63921155892, replyNumber=0, likeNumber=58, createdTime=2022-04-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a63921155892, moduleTitle=Lancet Oncol：杜鲁伐单抗联合立体定向放疗明显改善早期NSCLC患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a63921155892)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2069021, encodeId=a822206902157, content=<a href='/topic/show?id=bbd816043f2' target=_blank style='color:#2F92EE;'>#SCLC患者#</a>, objectTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, objectType=article, longId=214236, objectId=1c8821423607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8821423607, replyNumber=0, likeNumber=64, createdTime=2021-11-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8821423607, moduleTitle=Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8821423607)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SCLC患者

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Thorac Cancer：回顾性分析多西他赛联合雷莫芦单抗（ramucirumab）二线治疗化疗联合免疫治疗进展的晚期NSCLC患者的疗效

2021-12-13

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Clin Cancer Res：Selpercatinib在已发生脑转移的RET融合阳性NSCLC患者中的疗效(LIBRETTO-001研究)

2021-10-28

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Thorac Onco：奥希替尼单药抗NSCLC患者未放疗过的CNS转移灶的疗效

2021-09-15

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2022-05-16

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

ASCO2021: Nivolumab + Ipilimumab可使晚期NSCLC患者获益（CheckMate-227的4年数据）

2022-04-17

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Clin Cancer Res：Tepotinib治疗MET外显子14 (METex14)跳跃NSCLC患者的疗效和安全性：VISION研究

2022-06-09

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Lung Cancer: 纳武利尤单抗（nivolumab）治疗既往治疗过的晚期NSCLC患者的2年生存：来自法国、德国和加拿大的真实世界研究

2021-10-26

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Thorac Oncol：布里加替尼治疗晚期ALK+NSCLC患者的初步结果

2022-03-11

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Thorac Oncol：纳米-紫杉醇 vs 多西他赛治疗晚期NSCLC患者的疗效

2021-10-25

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Cancer Cell：吴一龙，周清教授发现靶向联合抗血管新生对EGFR突变NSCLC患者获益显著(ARTEMIS-CTONG1509研究）

2022-05-19

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

JAMA Oncol：术后放疗（PORT）治疗手术完全切除并完成术后辅助化疗的pIIIA-N2 NSCLC患者的疗效和安全性：III期临床研究PORT-C

2021-09-15

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Front Oncol： EGFR-TKIs新辅助治疗可手术切除NSCLC患者的疗效和安全性

2022-08-22

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Thorac Oncol：德瓦鲁单抗（durvalumab）维持治疗在EGFR和HER2突变不可切除III期NSCLC患者的作用

2021-11-11

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Immunother Cancer：抗生素对派姆单抗治疗的NSCLC患者的预后具有显著的负性效应！

2022-03-22

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

AACR年会：新辅助免疫治疗将NSCLC患者的病理完全反应率提高12倍！

2022-02-05

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

J Clin Oncol：晚期NSCLC患者围手术期加用度伐单抗显著提高了1年EFS率

2022-06-18

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果

2021-05-04

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

ASCO2021:德瓦鲁单抗可改善不可切除III期NSCLC患者的5年生存期和无进展生存

2022-04-04

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Lancet Oncol：杜鲁伐单抗联合立体定向放疗明显改善早期NSCLC患者预后

2022-04-25

jklm09 (审核中...)

前往app查看评论内容

#SCLC患者#

Lung Cancer：达可替尼（dacomitinib）一线治疗亚洲人群EGFR突变阳性NSCLC患者的疗效和安全性：3期研究ARCHER 1050的结果

2021-11-02

科室
- - 订阅+
  - 更多科室
工具
服务